Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment f… (NCT07514793) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
China37 participantsStarted 2026-04
Plain-language summary
This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for advanced mesothelioma.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Both male and female patients aged 18 to 75 years (inclusive).
* Histopathologically confirmed advanced mesothelioma.
* No prior systemic therapy.
* At least one measurable lesion according to mRECIST 1.1 and RECIST 1.1 criteria.
* Life expectancy ≥ 3 months.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
* Adequate major organ function, meeting the following laboratory criteria: Hemoglobin (Hb) ≥ 90 g/L.White blood cell count ≥ 3.0 × 10⁹/L.Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L.Platelet count (PLT) ≥ 100 × 10⁹/L.Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN).Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.Serum creatinine clearance (CrCl) ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
* Subjects agree to use effective contraceptive methods from the time of signing informed consent until 120 days after the last dose of study drug. Female subjects of childbearing potential must have a negative urine pregnancy test within 7 days before the start of treatment and must be non-lactating. A female patient is considered to have childbearing potential if she has experienced menarche, has not reached a postmenopausal state (≥12 consecutive months of amenorrhea with no identified cause other than menopause), and has not undergone sterilizat…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.